Clinical Trials
7 trialsNCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04116359 2020-09-28
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT01677949 2017-12-02
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01160731 2014-12-31
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Cancer Trials Ireland
Phase 1 Withdrawn
NCT00776802 2013-06-25
GCS-100LE
La Jolla Pharmaceutical Company
Phase 1/2 Withdrawn
NCT01416961 2012-08-22
Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT01563601 2012-08-15
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Withdrawn